Print
Email
Print Edition StoriesNovartis AG said it is discontinuing late stage clinical trials for a drug candidate to treat lung cancer because the trial was unlikely to meet its endpoint.
Trials on the investigational cancer drug, called ASA404, will be terminated, resulting in a $120 million charge to the company, according to a Novartis press release. Switzerland-based Novartis, which houses its Institutes for Biomedical Research headquarters in Cambridge, said it would shift its focus to its other potential cancer treatments.
Novartis said interim results from a Phase 3 trial showed that ASA404 likely wouldn’t meet the primary endpoint of significantly extending overall survival when used in combination with chemotherapy for the treatment of advanced non-small cell lung cancer. The company said it acted on recommendations from an independent panel.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
